Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.
Knobel H, Miró JM, Mahillo B, Domingo P, Rivero A, Ribera E, Gonzalez J, Sanz J, González A, Blanco JL, Boix V, Force L, Llibre JM, Dalmau D, Arroyo JA, De la Torre J, Rodriguez D, Montes ML, Arranz A, Sarasa M; Grupo Estudio Syndrome Immunodeficiencies Adquirida 26/02 Study Group. Knobel H, et al. Among authors: gonzalez j, gonzalez a. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1276-81. doi: 10.1097/01.qai.0000137372.18814.34. J Acquir Immune Defic Syndr. 2004. PMID: 15385735 Clinical Trial.
Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy.
Domingo P, Suarez-Lozano I, Torres F, Pomar V, Ribera E, Galindo MJ, Cosin J, Garcia-Alcalde ML, Vidal F, Lopez-Aldeguer J, Roca B, Gonzalez J, Lozano F, Garrido M; VACH Cohort Study Group. Domingo P, et al. Among authors: gonzalez j. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):582-7. doi: 10.1097/QAI.0b013e3181adcb01. J Acquir Immune Defic Syndr. 2009. PMID: 19512939
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Pulido F, et al. Among authors: gonzalez j. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50. doi: 10.1097/00126334-200404010-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15097150
Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study.
Perez-Elias MJ, Garcia-Arota I, Muñoz V, Santos I, Sanz J, Abraira V, Arribas JR, González J, Moreno A, Dronda F, Antela A, Pumares M, Martí-Belda P, Casado JL, Geijos P, Moreno S; Realvirfen study group. Perez-Elias MJ, et al. Among authors: gonzalez j. Antivir Ther. 2003 Dec;8(6):577-84. Antivir Ther. 2003. PMID: 14760891 Clinical Trial.
[Renal transplantation in patients with HIV infection].
Trullás JC, Miró JM, Barril G, Ros S, Burgos FJ, Moreno A, Mazuecos A, Alvarez-Vijande R, Oppenheimer F, Carmen Sánchez M, Blanco JL, Tuset M, Torre-Cisneros J, Polo R, González J. Trullás JC, et al. Among authors: gonzalez j. Enferm Infecc Microbiol Clin. 2005 Jun-Jul;23(6):363-74. doi: 10.1157/13076177. Enferm Infecc Microbiol Clin. 2005. PMID: 15970170 Review. Spanish.
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
Iribarren JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, González J, Moreno S, Arrizabalaga J, Chamorro L, Clotet B, Gatell JM, López-Aldeguer J, Martínez E, Polo R, Tuset M, Viciana P, Santamaría JM, Kindelán JM, Ribera E, Segura F; Grupo de Estudio de Sida; Consejo Asesor Clínico del Plan Nacional sobre el Sida del Ministerio de Sanidad y Consumo. Iribarren JA, et al. Among authors: gonzalez j. Enferm Infecc Microbiol Clin. 2004 Dec;22(10):564-642. doi: 10.1157/13069520. Enferm Infecc Microbiol Clin. 2004. PMID: 15596051 Spanish.
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Berenguer J, et al. Among authors: gonzalez j. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Clin Infect Dis. 2008. PMID: 18781872 Clinical Trial.
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, Muriel A, Fanjul F, Portilla J, Muñoz J, Amador C, de Zárraga MA, Vivancos MJ, Moreno S; Spanish HIV Research Network (CoRIS). Serrano-Villar S, et al. Lancet HIV. 2020 Aug;7(8):e565-e573. doi: 10.1016/S2352-3018(20)30202-2. Lancet HIV. 2020. PMID: 32763219 Clinical Trial.
7,175 results